drugset / Trial / NCT05936567

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

NCT05936567

Phase 2 Completed 136 enrolled Incyte Corporation
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is being conducted to evaluate the efficacy and safety of povorcitinib in adults with CSU that is inadequately controlled using SOC treatments.

Timeline

Start
2023-07-31
Primary completion
2025-02-28
Completion
2025-10-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Povorcitinib Small molecule